# Pizarra — PT-pseudo_06b319f42fcb (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_06b319f42fcb
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.452 ng/mL²
  - PSA velocity: 1.92 ng/mL/yr
  - Prior PSA: 12.3 ng/mL
  - Prostate volume: 29.86 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8947026 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: valsartan, metoprolol, tiotropium, salbutamol PRN, tamsulosin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.5 ng/mL. PI-RADS 5. PSAD 0.45. Prostate volume 30 mL. csPCa 0.89.

Vitals: weight 84 kg, height 186 cm, BMI 24.3, BP 129/83 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Current clinical focus centers on reassessing known ISUP GG1 pathology alongside a PSA reading of 13.5 ng/mL.

History: A retired civil servant first entered investigation for elevated PSA markers in early 2023. The individual is married and shares a home with his partner. He maintains a strictly non-smoking status. Medical background includes hypertension, chronic obstructive pulmonary disease, chronic kidney disease, and benign prostatic hyperplasia. Current pharmacotherapy consists of valsartan, metoprolol, tiotropium, and salbutamol on a PRN basis, alongside tamsulosin for lower urinary tract symptoms. Cardiology and pulmonary assessments have recently confirmed stable parameters. Daily mobility includes a twenty-minute walking routine, though he experiences intermittent fatigue that does not correlate with physical activity. Lower urinary tract symptom severity registers at an IPSS score of 13. Two systematic biopsies performed in 2023 and 2024 both revealed Gleason 3+3 disease, placing him under ongoing surveillance. A routine colonoscopy and a recent influenza vaccination occurred without complication. He reports no alterations in bowel habits, unexplained weight shifts, hematuria, pelvic discomfort, or bone pain. Overall systemic health remains steady.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents with symmetrical enlargement and lacks any palpable nodules. Systemic assessment shows stable vital signs, recording a blood pressure of 129/83 mmHg and a regular heart rate of 64 bpm. Abdominal palpation yields no masses, and peripheral lymphatic examination remains entirely unremarkable.

Patient info: retired civil servant; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Gastroenterology — surveillance colonoscopy; GP practice nurse — flu vaccination.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.76 +/- 0.11   (95% CI 0.55-0.97)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.11  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.79 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size and zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy decision, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the context that the patient has a prior positive biopsy, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior did not weigh the specific PI-RADS 5 score against the prior positive biopsy status, nor did it weigh the rising PSA velocity (1.92 ng/mL/yr) in conjunction with the prior Gleason 3+3 diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.76) based on the visible data, but the guideline criterion explicitly states the panel is inconclusive because the prior positive biopsy means the decision hinges entirely on retrieved documents (MRI, PSA trend, notes). The prior failed to account for the uncertainty introduced by the prior diagnosis, potentially leading to an overestimation of the need for immediate action. Furthermore, the high aleatoric uncertainty (H=0.79) suggests the data itself is highly mixed regarding the correct path.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology / mpMRI report (get_mri_report) -> To determine if the current PI-RADS 5 lesion size and zone compare against an earlier study, which is crucial for assessing progression.
psa_trend (get_psa_trend) -> To establish the serial PSA trend beyond the headline value, which is necessary to assess the significance of the 1.92 ng/mL/yr velocity.
previous_notes (get_previous_notes) -> To ascertain the prior grade, surveillance pathway, and management agreement, which directly addresses the guideline criterion.

GUIDELINE ANCHOR
The guideline criterion states that the visible panel does not determine the decision; the decision must come from retrieved documents to determine if a surveillance re-biopsy is due.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate mpMRI | Date: 10 February 2025 | Department: Radiology
PI-RADS 5 lesion in the right mid-gland peripheral zone.
The report describes a 14 x 12 x 10 mm hypointense focus with diffusion restriction and early focal enhancement. It does not explicitly compare this finding to a previous MRI.

get_psa_trend
{"date": "Mar 2023", "val": 4.2}, {"date": "Nov 2023", "val": 6.2}, {"date": "Jun 2024", "val": 9.1}, {"date": "Feb 2025", "val": 13.5}
The PSA trend shows a clear rising trajectory, with the value increasing from 4.2 ng/mL in Mar 2023 to 13.5 ng/mL in Feb 2025.

get_previous_notes
{"date": "27 Oct 2024", "author": "Dr. F. de Boer (GP)", "text": "A biopsy conducted in 2023 established ISUP GG1 disease. Subsequent testing in June 2024 yielded a PSA reading of 12.3 ng/mL, which triggered further urological referral. The individual remains on tamsulosin for lower urinary tract symptoms and maintains stable COPD management via tiotropium."}, {"date": "29 Jun 2024", "author": "Dr. F. de Boer (GP)", "text": "Pathology from that session returned Gleason 3+3, ISUP GG 1. Routine laboratory rechecking was scheduled alongside standard symptom tracking."}
The previous notes confirm a prior biopsy result of Gleason 3+3 (ISUP GG1) from 2023, and the patient was under surveillance.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend: Rising trajectory, with the value increasing from 4.2 ng/mL in Mar 2023 to 13.5 ng/mL in Feb 2025.
- MRI report: PI-RADS 5 lesion identified, which is a high-risk finding.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy result was Gleason 3+3 (ISUP GG1), suggesting a low-grade diagnosis.

WHERE THIS LEANS
The evidence strongly suggests progression or recurrence given the rising PSA trend and the new PI-RADS 5 finding, which contradicts the low-grade prior diagnosis.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a significant rising PSA trend and a high-risk PI-RADS 5 finding against a prior low-grade diagnosis, strongly supports the recommendation for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The statistical prior suggested biopsy (p=0.76) and its 'firm' tier was not contradicted by the retrieved evidence. The evidence strongly supports sampling because the rising PSA trend (4.2 to 13.5 ng/mL) combined with the new PI-RADS 5 finding contradicts the prior low-grade diagnosis of Gleason 3+3. The conference converged on biopsy because the retrieved documents showed progression indicators that warranted further tissue sampling.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
